PF-3758309

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

P21-activated kinase inhibitor

Related drugs:

‹

›

PAK1 overexpression	T Cell Non-Hodgkin Lymphoma	PAK1 overexpression	T Cell Non-Hodgkin Lymphoma	FRAX597 + PF-3758309 Resistant: C3 – Early Trials FRAX597 + PF-3758309 Resistant : C3	FRAX597 + PF-3758309 Resistant: C3 – Early Trials FRAX597 + PF-3758309 Resistant : C3
PAK2 overexpression	T Acute Lymphoblastic Leukemia	PAK2 overexpression	T Acute Lymphoblastic Leukemia	FRAX597 + PF-3758309 Sensitive: D – Preclinical FRAX597 + PF-3758309 Sensitive : D	FRAX597 + PF-3758309 Sensitive: D – Preclinical FRAX597 + PF-3758309 Sensitive : D

Associations
(2)